Envista’s Q2 Momentum: Guidance Raised, VBP Finally Visible, and Innovation Accelerating

Envista delivered a strikingly strong second quarter, with core sales up 5%, adjusted EBITDA up 28%, and EPS up 58%, driving management to raise full-year guidance for the second consecutive quarter. “In the second quarter, we continued our momentum in executing on our growth and operational plans, delivering a strong first half to the year with core growth of just over 7%.” — Paul Keel, President and Chief Executive Officer · 2026-08-05 The resilience of the dental market, balanced contributions across segments and geographies, and disciplined execution under the Envista Business System have put the company on a clear upward trajectory.

What Changed: Clarity on VBP, IEEPA Refunds, and a Guidance Raise

The most notable shift is the newfound visibility on China's volume-based procurement (VBP). After months of uncertainty, management confirmed both ortho VBP 1.0 and implant VBP 2.0 processes are underway and anticipated to complete in the second half. “The new news, we have heard now that both the ortho 1.0 and implants 2.0 processes are underway.” — Paul Keel, President and Chief Executive Officer · 2026-08-05 Based on prior implant VBP experience, they expect a ~40-45% price cut in ortho offset by volume gains, and a more modest ~10-15% price reduction in implants with share gains. This clarity removes a major overhang, and management has embedded these assumptions into the raised guidance.

Equally important is the tailwind from IEEPA tariff refunds. While excluded from adjusted earnings, the $13 million recovery in Q2 boosted free cash flow and contributed to a 158% conversion rate. CFO Eric Hammes noted, “Q2 free cash flow was $105 million, a $29 million increase over the second quarter of last year, driven by improved profitability as well as the $13 million recovery related to IEEPA tariffs paid in 2025.” — Eric Hammes, Chief Financial Officer · 2026-08-05 With balance sheet net leverage at just 0.7x, the company retains ample flexibility for both organic investment and M&A.

The guidance raise itself is a signal of confidence. Core growth is now expected at 3.5-4.5% (up from 2-4%), adjusted EBITDA +11-14%, and EPS of $1.50-1.55 — with a notable drop in the tax rate to ~26% from prior 28%. This is not merely a beat-and-raise; it reflects a structural improvement in profitability and a sustainable tax base. New product launches — including Versah (osseodensification) and the ZenSeal Pro endodontic sealer — are beginning to contribute to the innovation engine, and price capture remains strong across most markets ex-China.

Why It Matters: Margin Expansion, Investor Day, and a Reasonable Valuation

Envista’s operating leverage is becoming more visible: gross margin expanded 70 bps, and EBITDA margin rose 230 bps to 14.7%. This is being driven by volume, price, productivity, and favorable FX, even as the company reinvests heavily in R&D and sales and marketing. Gross margin, which has been rangebound in the mid-50s for years, expanded to 55.1% in Q2. The leadership team will have the chance to detail the next phase of value creation at the September 17 Investor Day, where they plan to showcase innovation priorities across the four main businesses. As Paul Keel put it,

We recently announced an Investor Day coming up in about 6 weeks on Thursday, September 17. The event will include an update on our progress executing the value creation plan that we laid out in March of 2025 as well as some insights into innovation priorities for our 4 main businesses.

This stands in contrast to prior quarters where uncertainty around tariffs and VBP dominated. In the Q1 2026 call, Paul had emphasized investments beginning to bear fruit, “The investments we're making in areas like clinical education and customer support and new product development are all beginning to bear fruit.” — Paul Keel, President and Chief Executive Officer · 2026-05-06 Now the evidence is more concrete, with six consecutive quarters of broad-based growth and a clear handoff to margin expansion. The VBP 2 dynamics will be worth watching, but the company’s track record from the first implant VBP — where net margin dollars actually grew — suggests they can navigate the transition. With the billing day effect creating a temporary Q4 growth dip, investors should focus on the normalized ~4% underlying growth. The stock, trading around 1.5x revenue and 17x operating income, has room to re-rate if margins continue to expand. The market has yet to fully appreciate the earnings power acceleration — EPS growth of 58% in the quarter, sustained growth investments, and an improving tax rate create a compelling equation for the second half and into 2027.